The author is shorting Exelixis, citing a r/stock post claiming a generic version of its main income source just received approval. The mechanism is that generic competition erodes the branded drug's revenue, and the catalyst is underappreciated because the relevant press releases originated from Taiwan and flew under the radar. The author frames this as a contrarian, under-covered short opportunity.